Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Protalix Biotherapeutics Inc    PLX

Delayed Quote. Delayed  - 08/26 09:59:04 pm
0.61 USD   -1.04%
08/10 Protalix BioTherapeutics Announces Additional Positive Data from ..
08/09 PROTALIX BIOTHE : reports 2Q loss
08/08 Protalix BioTherapeutics Reports Second Quarter 2016 Financial Re..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
08/22/2016 08/23/2016 08/24/2016 08/25/2016 08/26/2016 Date
0.6273(c) 0.6131(c) 0.6199(c) 0.6164(c) 0.61 Last
200 489 173 499 222 741 39 473 126 025 Volume
+1.18% -2.26% +1.11% -0.56% -1.04% Change
More quotes
Financials ($)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
P/E ratio 2013 -
P/E ratio 2014
Capi. / Sales2013 3,91x
Capi. / Sales2014 1,72x
Capitalization 61,5 M
More Financials
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system.It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.Its drug... 
More about the company
Surperformance© ratings of Protalix Biotherapeutics I
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTALIX BIOTHERAPEUTICS I
08/10 PROTALIX BIOTHERAPEUTICS, INC. : Other Events (form 8-K)
08/10 Protalix BioTherapeutics Announces Additional Positive Data from its Phase I/..
08/09 PROTALIX BIOTHERAPEUTICS : reports 2Q loss
08/08 PROTALIX BIOTHERAPEUTICS : Management's Discussion and Analysis of Financial Con..
08/08 PROTALIX BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition (..
08/08 Protalix BioTherapeutics Reports Second Quarter 2016 Financial Results
07/21 PROTALIX BIOTHERAPEUTICS : Findings from Y. Tekoah et al in Plant Biotechnology ..
07/07 PROTALIX BIOTHERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits..
07/07 Protalix BioTherapeutics Announces First Patient Dosed in the AIR DNase&trade..
06/07 PROTALIX BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements ..
More news
Sector news : Biotechnology & Medical Research - NEC
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/22DJPfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix Biotherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 6,50 $
Spread / Average Target 940%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Moshe Manor President, Chief Executive Officer & Director
Shlomo Yanai Chairman
Tzvi Palash Chief Operating Officer
Yossi Maimon CFO, Secretary, Treasurer & Vice President
Yoseph Shaaltiel Executive Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PROTALIX BIOTHERAPEUTI..-39.23%62
INCYTE CORPORATION-26.14%15 499
CELLTRION, INC.--.--%11 596
LONZA GROUP AG14.78%10 334
QUINTILES TRANSNATIONA..10.22%8 935
ALKERMES PLC-44.36%6 737
More Results